Secukinumab

• CAT Number: I044215
• CAS Number: 1229022-83-6
• Purity: ≥95%

Secukinumab（Cat No.:I044215）is a fully human monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune responses. By neutralizing IL-17A, secukinumab reduces inflammation and halts the progression of immune-mediated diseases. It is approved for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Administered via subcutaneous injection, secukinumab offers rapid and sustained symptom relief, improving skin clarity and joint function. Its targeted mechanism provides an effective treatment option with a favorable safety profile for patients with chronic inflammatory conditions.